联系方式：400-650-8506
CNEN
产品名称 VX 661 - Tezacaftor
产品货号 Axon 2169 CAS [1152311-62-0] MF C26H27F3N2O6MW 520.50 Purity: 99% Optical purity: Optically pure Soluble in DMSO Description Corrector of the cystic fibrosis transmembrane conductance regulator (CFTR), hypothesized to restore F508del mutation processing and plasma membrane localization of CFTR protein, thereby effectively increasing functional surface CFTR ion channels. VX 661 is the second CFTR corrector in line with VX 809 (first), and VX 983 (third), and is believed to help CFTR protein reach the cell surface. Tested in phase 2 to evaluate safety, efficacy, pharmacokinetics, and pharmacodynamics in subjects with cystic fibrosis suffering from the F508del-CFTR mutation. References Certificates Categories Extra info Vertex Pharmaceuticals Incorporated. Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation. ClinicalTrials.gov [Online]. 2012.   A. Opar. Excitement mounts for first disease-modifying cystic fibrosis drugs. Nat. Rev. Drug. Discov. 2011, 10, 479-480. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology CFTR EC 3.6.3.49 Corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) Chemical name (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide Parent CAS No. [1152311-62-0] Order Size Unit Price Stock 5 mg €105.00 In Stock
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

VX 661 - Tezacaftor

Based on 18 reference(s) in Google Scholar 9 10 18

Axon 2169

CAS [1152311-62-0]

MF C26H27F3N2O6
MW 520.50

  • Purity: 99%
  • Optical purity: Optically pure
  • Soluble in DMSO

VX 661

Description

Corrector of the cystic fibrosis transmembrane conductance regulator (CFTR), hypothesized to restore F508del mutation processing and plasma membrane localization of CFTR protein, thereby effectively increasing functional surface CFTR ion channels. VX 661 is the second CFTR corrector in line with VX 809 (first), and VX 983 (third), and is believed to help CFTR protein reach the cell surface.

Tested in phase 2 to evaluate safety, efficacy, pharmacokinetics, and pharmacodynamics in subjects with cystic fibrosis suffering from the F508del-CFTR mutation.
产品资料